amx0035
Generic: sodium phenylbutyrate and taurursodiol
amx0035: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | Phase 2 |
FDA Decisions
FDA_MeetingCompany plans to meet with the FDA and other stakeholders to inform a Phase 3 program and expects to provide an update in 2025.(AMLX)
Frequently asked questions
Who is developing amx0035?
amx0035 is being developed by Amylyx Pharmaceuticals, Inc..
What is amx0035's latest FDA decision?
The most recent tracked FDA decision for amx0035 is FDA_Meeting for Company plans to meet with the FDA and other stakeholders to inform a Phase 3 program and expects to provide an update in 2025..
Get deeper analysis on amx0035
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis